Worldwide Market for Cancer Diagnostics, 4th Edition, The now available at ReportsandReports

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.
These changes and more are addressed in Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
• Histology/Cytology
• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
• Immunoassay Lab Based Cancer Test Sales
• Pap Smear Testing Volumes
• World Cancer Statistics
• POC Tests
• DNA Reagents for Cancer Testing
• CTC Testing Markets
• Biochip Innovations
• New Companies with Novel Approaches
• “Laggard” Companies Who Have Not Met Expectations
• Major Protein and Molecular Markers Used in Tissue Staining
• Biomarkers Under Investigation
• Acquisitions and Mergers
• Status of PGx Testing
• Microarray Markets in Clinical Labs
• Lists of Vendors and Major Products
• Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:
• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
• Tests for specific cancers, and
• Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.

Table OF Contents
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Test Segments
Geographic Distribution
Market Trends
Death Rates
Revolutionary Therapeutics
Physician Factor
Consumer Lobby
Price

CHAPTER TWO: Introduction
Background
Pharmacogenomics
Test Service Commercialization
Cancer – Diagnosis and Therapy Management
Point of View

CHAPTER THREE: Market Trends In The Commercialization Of Cancer Diagnostics
Background
Demographics of Cancer, a Global Phenomenon
Cancer Testing in the World:
Screening and Government Supported Programs
United States of America
International
Europe
Mexico
China
India
Reimbursement and Commercialization of Novel Tests
Test Services – Route for Cancer Innovation
Table 3-3
Regulatory requirements of new products
Strategic Alliances and Partnerships
Personalized Medicine Advances
Gene Patents and Test Commercialization

CHAPTER FOUR: Technological Trends
Background
Biomarker Revolution
The promise of Personalized Medicine
Miniaturization and Multiplexed Biological Assays
The emergence of non-invasive tools
New Technologies Applied To Cancer Diagnostics
Overview
New Platforms
Mass Spectrometry
Chromosome Analysis
Next-Generation Sequencing
RNA – Ribonucleic Acid
The In Vitro/In Vivo Mix

CHAPTER FIVE: Market Analysis
Background
World Regional Segments of the Market for Cancer Diagnostics
Companies and Products
Has Screening Lost its Allure?
Cancer Specific Tests
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer

CHAPTER SIX: Cancer Tests in IVD Segments (Segment Analysis)
Cancer Diagnostics and IVD Markets
The Market For Cancer Tests In Clinical Chemistry
The Market For Immunoassay Cancer Tests, Lab & Rapid
Point-of-care
The Market for Cancer Tests in Histology / Cytology
Traditional Tissue Stains
Pap Smear and HPV Testing
IHC/ISH
The Market for Tissue Microarrays
The Market For Cancer Tests in Flow Cytometry
The Market for Circulating Tumor Cells in Cancer Diagnostics
The Market For Cancer Molecular Assays
The Market For Cancer Tests in Pharmacodiagnostics
The market for Biochips and Arrays in Cancer Diagnostics
The Commercial Outlook for Cancer Diagnostics

CHAPTER SEVEN: Conclusions
Conclusions and Strategic Implications
Conclusion 1
Implication:
Conclusion 2
Implication:
Conclusion 4
Implication
Conclusion 5
Implication:
Conclusion 6:
Unmet Market Needs
Unmet Need #1
Unmet Need #2
Unmet Need #3

CHAPTER EIGHT: The Top Tier of IVD Companies and their investment in cancer diagnostics
Abbott Diagnostics
Molecular Histology
Molecular Diagnostics
Immunoassays
Beckman Coulter Inc
FOB
Flow Cytometry
Becton, Dickinson and Company (BD)
Histology
bioMerieux Inc
Bio-Rad Laboratories Inc
Dako A/S
Fujirebio Diagnostics, Inc
Gen-Probe Inc
Hologic, Inc
Histology
HPV
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V
Roche Diagnostics Indianapolis, IN www.roche.com Recent Revenue History ($ million)
Histology
Immunoassays
PCR
Research
Siemens Medical Solutions Diagnostics
Molecular
In Vivo
Sysmex Corporation

CHAPTER NINE: The Status Quo in Cancer Diagnostics
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc
Aperio Technologies, Inc
Asuragen, Inc
AviaraDx
Binding Site (The) Ltd
BioCurex Inc
BioGenex Laboratories, Inc
BioImagene
Bio-Reference Laboratories, Inc
Biotage AB
bioTheranostics
BioView Ltd
Celera Diagnostics
China Medical Technologies, Inc
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc
CytoCore, Inc
DxS Ltd
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc
Ikonisys, Inc
InterGenetics Inc
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc
mtm laboratories AG
Myriad Genetics, Inc
Nanosphere, Inc
OncoVista Innovative Therapies, Inc
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc
Quest Diagnostics
Response Genetics, Inc
Rosetta Genomics Ltd
Sequenom
Transgenomic Inc
Veridex, LLC
Vermillion Inc
Zila, Inc

CHAPTER TEN: New Entrants And Novel Product Developers
20/20 GeneSystems, Inc
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc
Advalytix
Affymetrix, Inc
Allegro Diagnostics
Althea Technologies, Inc
Amorfix Life Sciences Ltd
Arbor Vita Corporation
ArcticDx Inc
Arrayit Diagnostics Inc
AVEO Pharmaceuticals, Inc
Axela, Inc
Baypoint Biosystems, Inc
Biodesix, Inc
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc
Caris Diagnostics
Castle Biosciences Inc
Celerus Diagnostics
Cell Biosciences
CeMines, Inc
Cepheid
ChromoCure Inc
Chronix Biomedical Inc
Clinical Genomics Pty Ltd
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc
Compugen Ltd
Correlogic Systems, Inc
CS-Keys, Inc
deCode Genetics Inc. —
DiaGenic ASA
DiagnoCure –
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc
Expression Pathology Inc
Falcon Genomics, Inc
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V
Intrinsic Bioprobes Inc
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc
IRIS International, Inc
MabCure Inc
MacroArray Technologies, LLC
MagArray Inc
Martell Biosystems, Inc
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc
Miraculins Inc
MolecularMD Corp
Neogenix Oncology, Inc
NextGen Sciences
Nuvera Biosciences
Olink AB
Oncimmune LLC
OncoMethylome Sciences S.A
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc
Provista Life Sciences LLC
Rubicon Genomics, Inc
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc
Skyline Diagnostics B.V
Source MDx
Soar BioDynamics, Ltd
Strategic Diagnostics Inc
Synergenz Bioscience Ltd
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc
Vitatex Inc
WaferGen Biosystems, Inc
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd

In-depth Analysis of the Leading Healthcare Biotechnology Companies

Top 10 Biotech Companies Market Report ( http://www.bharatbook.com/Market-Research-Reports/Top-10-Biotech-Companies-Market-Outlook-2008-2023.html ) examines the product portfolios of the leading companies critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.
 
 The leading healthcare biotechnology companies will continue to make strong inroads into the overall global pharma industry and market in the years ahead, with rising stars competing too. Do you know how sales of leading biotech companies will develop over the coming years? Do you know the prospects for other biotech organisations? Concludes that there will be increasing reliance on biological drugs as time goes by, especially for recalcitrant diseases with significant unmet needs. The commercial and technological opportunities for greater personalisation of medicine through biotechnology are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech companies are significant. The development of more-personalised medicine promising greater efficacy and safety – particularly in cancer treatment – is a major commercial hope. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.
 
 The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics – amongst others – the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. Our new report – Top-10 Biotech Companies – Market Outlook, 2008-2023 – will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore.
 
 Over the period 2008 to 2023, the healthcare biotechnological market continuing its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development. There remain significant unmet needs in this market, with great opportunities for companies that can develop safer and better-targeted treatments.
 
 For more information please visit : http://www.bharatbook.com/Market-Research/Biotechnology.html
 
 Or
 
 Contact us at:
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com
 Website: www.bharatbook.com